Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data

Background Cardiomyopathy is a common cause of atrial fibrillation (AF) and may also present as a complication of AF. However, there is a scarcity of evidence of clinical outcomes for people with cardiomyopathy and concomittant AF. The aim of the present study was therefore to characterize the prevalence of AF in major subtypes of cardiomyopathy and investigate the impact on important clinical outcomes. Methods and Results A retrospective cohort study was conducted using electronic medical records from a global federated health research network, with data primarily from the United States. The TriNetX network was searched on January 17, 2021, including records from 2002 to 2020, which included at least 1 year of follow‐up data. Patients were included based on a diagnosis of hypertrophic, dilated, or restrictive cardiomyopathy and concomitant AF. Patients with cardiomyopathy and AF were propensity‐score matched for age, sex, race, and comorbidities with patients who had a cardiomyopathy only. The outcomes were 1‐year mortality, hospitalization, incident heart failure, and incident stroke. Of 634 885 patients with cardiomyopathy, there were 14 675 (2.3%) patients with hypertrophic, 90 117 (7.0%) with restrictive, and 37 685 (5.9%) with dilated cardiomyopathy with concomitant AF. AF was associated with significantly higher odds of all‐cause mortality (odds ratio [95% CI]) for patients with hypertrophic (1.26 [1.13–1.40]) and dilated (1.36 [1.27–1.46]), but not restrictive (0.98 [0.94–1.02]), cardiomyopathy. Odds of hospitalization, incident heart failure, and incident stroke were significantly higher in all cardiomyopathy subtypes with concomitant AF. Among patients with AF, catheter ablation was associated with significantly lower odds of all‐cause mortality at 12 months across all cardiomyopathy subtypes. Conclusions Findings of the present study suggest AF may be highly prevalent in patients with cardiomyopathy and associated with worsened prognosis. Subsequent research is needed to determine the usefulness of screening and multisdisciplinary treatment of AF in this population.

[1]  S. Matsuo,et al.  Comparison of atrial arrhythmia recurrence after persistent atrial fibrillation ablation between patients with or without tachycardia‐induced cardiomyopathy , 2019, Journal of cardiovascular electrophysiology.

[2]  S. Prabhu,et al.  Atrial Remodeling Following Catheter Ablation for Atrial Fibrillation-Mediated Cardiomyopathy: Long-Term Follow-Up of CAMERA-MRI Study. , 2019, JACC. Clinical electrophysiology.

[3]  K. Ellenbogen,et al.  Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[4]  Stefan L. Zimmerman,et al.  Hypertrophic Cardiomyopathy Patients With Paroxysmal Atrial Fibrillation Have a High Burden of Left Atrial Fibrosis by Cardiac Magnetic Resonance Imaging. , 2019, JACC. Clinical electrophysiology.

[5]  M. Shoda,et al.  Long-term clinical course after catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy , 2018, Heart and Vessels.

[6]  D. Mutlak,et al.  Risk Score for Prediction of 10-Year Atrial Fibrillation: A Community-Based Study , 2018, Thrombosis and Haemostasis.

[7]  S. Prabhu,et al.  Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. , 2017, Journal of the American College of Cardiology.

[8]  G. Giannakoulas,et al.  Atrial fibrillation in hypertrophic cardiomyopathy: A turning point towards increased morbidity and mortality. , 2017, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[9]  L. Fauchier,et al.  Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. , 2016, The American journal of medicine.

[10]  Steven G. Johnson,et al.  A Harmonized Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic Health Record Data , 2016, EGEMS.

[11]  J. Le Heuzey,et al.  Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study , 2013, Circulation.

[12]  H. Calkins,et al.  Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2013, Heart rhythm.

[13]  Bee Hoon Heng,et al.  A comparison of comorbidities obtained from hospital administrative data and medical charts in older patients with pneumonia , 2011, BMC health services research.

[14]  G. Barbati,et al.  Impact of Atrial Fibrillation on Outcome of Patients with Idiopathic Dilated Cardiomyopathy: Data from the Heart Muscle Disease Registry of Trieste , 2010, Clinical Medicine & Research.

[15]  M. Pfeffer,et al.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, Journal of the American College of Cardiology.

[16]  A. Kitabatake,et al.  Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan. , 2000, Japanese circulation journal.

[17]  Adrian Baranchuk,et al.  Atrial fibrillation in patients with inherited cardiomyopathies , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.